

INVESTIGATIONAL DEVICE and/or DRUG USAGE
IN RESEARCH & DEVELOPMENT SERVICE

1. **PURPOSE:** To establish a service level policy for the use of investigational device and drugs, including the emergency or one-time treatment use of devices and/or drugs at the Portland VA Medical Center. This HRPP policy covers drugs only to be used on an emergency basis or for one-time treatment. **For more information concerning policy and procedures for investigational drug use, see the PVAMC Pharmacy Policy “Investigational Drugs for Human Use.”**
2. **POLICY:** The Department of Veterans Affairs clinical investigations of medical devices are subject to the Federal Food, Drug, and Cosmetic Act and unless exempted under certain specified conditions, are required to comply with Investigational Device Exemption (IDE) regulations as outlined in 21CFR812. VA investigators are expected to fulfill all of the responsibilities delineated in the Food & Drug Administration (FDA) regulations. Investigational devices in use at the Portland VA Medical Center (PVAMC) must be stored, secured, and dispensed in accordance with specific device requirements and as outlined in the research project. Principal Investigators are responsible for the appropriate storage, security, dispensing, and use of investigational devices at the PVAMC. The investigational devices may only be used at the PVAMC after:
 - a. The research project and associated documentation have been approved by the Institutional Review Board (IRB) and the Research & Development Committee (R&D), **excluding exceptions for the emergency or one-time treatment use of an unapproved medical device, investigational drug or drug for unapproved indication as outlined in this policy.**
 - b. The patient or legally authorized representative has signed the VA Research Consent Form (VA Form 10-1086), excluding exceptions from informed consent as outlined in this policy in section 5.c.
3. **DEFINITIONS:**
 - a. An **Investigational Device** as defined by the FDA, is a device that is the object of an investigation [21 CFR 812.3(g)]. Investigational devices include transitional devices (21 CFR 812.3(r)) that are objects of investigations. According to VHA Handbook 1200.5, July 15, 2003, (3.j.), an investigational device may be an approved device that is being studied for an unapproved use or efficacy.
 - b. An **Unapproved Device** is defined as a device that is used for a purpose or condition for which the device requires, but does not have, an approved application for pre-market approval under section 515 of the Federal Food, Drug, and Cosmetic (FD&C) Act [21 U.S.C. 360 (e)]. An unapproved device may be used in human subjects only if approved for clinical testing under an approved application for an Investigational Device Exemption (IDE) under section 520 (g) of the Act [21 U.S.C. 360(j)(g)] and 21 CFR 812. Medical devices that have not received marketing clearance under section 510(k) of the FD&C Act are also considered unapproved devices.
 - c. An **Investigation** is defined as a clinical investigation or research involving one or more subjects to determine the safety or effectiveness of a device [21 CFR 812.3(h)].
 - d. An **Investigator** is an individual who actually conducts a clinical investigation, i.e. under whose immediate direction the test article is administered or dispensed to, or used involving, a subject, or, in the event of an investigation conducted by a team of individuals, is the responsible leader of that team. [21 CFR 812.3(i)].
 - e. **Sponsor** means a person who takes responsibility for and initiates a clinical investigation. The **sponsor** may be an individual or pharmaceutical company, governmental agency, academic institution, private organization, or other organization.;
 - f. A **Sponsor-investigator** is an individual who both initiates and actually conducts, alone or with others, an investigation; that is, under whose immediate direction the investigational device is administered,

VA MEDICAL CENTER, PORTLAND, OREGON
Human Research Protection Program Policy & Procedure
Investigational Device and/or Drug Usage

Effective: 8/27/2007

dispensed, or used. The term does not include any person other than an individual. The obligations of a sponsor-investigator under this part include those of an investigator and those of a sponsor.

- g. A **Non-significant Risk Device** is one that does not present significant risk to the human subjects.
- h. A **Significant Risk Device** is one that presents a potential for serious risk to the health, safety or welfare of the human subjects. [21 CFR 812.3(m)] Such a device is
 - (1) intended for use as an implant;
 - (2) used in supporting or sustaining human life;
 - (3) intended for a use that is of substantial importance in diagnosing, curing, mitigating or treating disease, or otherwise preventing impairment of human health; or
 - (4) one that otherwise presents a potential for serious risk to the health, safety, or welfare of subjects.

4. RESPONSIBILITIES:

- a. The **Associate Chief of Staff / Research & Development** is responsible for developing and managing policies and procedures related to the use of investigational devices at the Portland VA Medical Center.
- b. The **Research and Development Committee** is responsible for the initial and continuing review of the scientific quality and appropriateness of and approving or disapproving the research projects involving investigational devices with human subjects.
- c. The **Institutional Review Board** is responsible for approving or disapproving research projects involving investigational devices in accordance with the procedures outlined in 5b below.
- d. **Principal Investigators** are responsible for:
 - (1) Submitting the scientific protocol and all required documentation, including the informed consent form and the IRQ Appendix E, "Investigative Devices," or Investigational Drug Information Record (10-9012) to the Research Service for IRB and R&D Committee review prior to beginning the study.
 - (2) Submitting continuing review documentation and all adverse events to the IRB in a timely manner.
 - (3) Using the investigational device or drug only after notification of IRB and R&D Committee approval and informed consent is obtained.
 - (4) Forwarding the original signed informed consent form (VA Form 10-1086) for each patient enrolled in the research project, emergency use protocol, or one-time treatment use protocol to the R&D Service for scanning into the patient's electronic medical record. After the informed consent form is scanned into the patient's electronic medical record, the original signed consent form will be forwarded to the Principal Investigator for inclusion in the Principal Investigator's case history files. A copy must be given to the patient and the patient must initial the original signed consent form acknowledging receipt of a copy of the informed consent form.
 - (5) Adhering to the Investigational Device Exemption regulations at 21 CFR 812. Research projects involving non-significant risk devices must adhere to the abbreviated requirements at 21 CFR 812.2 (d).
 - (6) Providing secure storage for all investigational devices according to their storage requirements as defined in the IRQ Appendix E, "Investigative Devices."
 - (7) Ensuring that all investigational devices are secured properly as defined in the IRQ Appendix E, "Investigative Devices."
 - (8) Providing accountability of all investigational devices as defined in the IRQ Appendix E, "Investigative Devices," or Investigational Drug Information Record (10-9012).
 - (9) Maintaining records and tracking of all investigational devices as defined in the IRQ Appendix E, "Investigative Devices."
 - (10) For investigational drugs, adhering to all requirements in the Investigational Drugs for Human Use Policy.
 - (11) Ensuring proper dispensing and utilization of the investigational devices as defined in the research project proposal.

5. PROCEDURES:

a. Local Research Projects and VA Cooperative Studies

Principal Investigators must adhere to the following procedures:

A research project proposal must be submitted to and approved by both the IRB and R&D Committee prior to use of the investigational device. An IDE for investigational devices or IND for investigational drugs must be obtained from the sponsor prior to project review.

- (1) For devices, submit all of the following documentation to the IRB for review:
 - (a) Review of prior data, including risk assessment data previously done by the sponsor and FDA;
 - (b) Source of the device;
 - (c) Literature survey (this should be a complete substantive review of the peer-reviewed medical literature);
 - (d) Scientific Protocol (protocol design as set forth for devices [21 CFR 812.25]);
 - (e) Initial risk assessment whether it is a significant or non-significant risk device;
 - (f) Initial Review Questionnaire (IRQ) Appendix E, "Investigational Devices."
 - (g) Significant Risk devices as determined by the FDA or IRB will require the investigator/sponsor to obtain an Investigational Device Exemption (IDE) from the FDA;
 - (h) Expected outcome;
 - (i) Administrative Review Form describing any costs accruing to the medical center;
 - (j) Proposed Informed Consent Form;
 - (k) Initial Review Questionnaire (IRQ); and
 - (l) Any other applicable documentation as outlined in the IRQ.
- (2) Store the investigational device in a locked and secured area as outlined in the Initial Review Questionnaire Appendix E, "Investigational Devices."
- (3) Dispense and use of the investigational device is limited to appropriate personnel as outlined in the research protocol.
- (4) Obtain and document informed consent for each individual prior to using the investigational device.
- (5) Maintain the appropriate research records and tracking of the investigational device per 21 CFR812.140.
- (6) Report the following protocol modifications to the IRB immediately and to the FDA within five days after making the modification. These modifications must not affect:
 - (a) the validity of data or information resulting from the completion of an approved protocol, or the relationship of likely patient risk to benefit relied upon to approve a protocol;
 - (b) the scientific soundness of the investigational plan; and
 - (c) the rights, safety, or welfare of the human subjects involved in the investigation
- (7) Obtain FDA and IRB approval prior to the following protocol modifications:
 - (a) Device indication;
 - (b) Study control type;
 - (c) Primary endpoint;
 - (d) Protocol modifications designed to terminate a clinical study earlier than originally planned; and/or
 - (e) Increase sample sizes or expand the number of investigational sites.

b. IRB Review of Medical Devices

- (1) The IRB must determine whether an investigational device is either of Significant Risk (SR) or Non-Significant Risk (NSR).
 - (a) The determination of level of risk of the device is based on the proposed use of the device and not on the device alone.

- (b) The designation of NSR for a device is independent of the designation of a study as minimal risk.
- (c) The IRB makes its decision of significant or non-significant risk level of the device based on the review and evaluation of the following:
 - the risk evaluation provided by the sponsor or sponsor-investigator investigator's brochure, if applicable federal regulations;
 - the FDA Information Sheet, "Significant Risk and Non-Significant Risk Medical Device Studies,"
 - any additional correspondence regarding the device that may be from the FDA, sponsor, and/or investigator;
 - the nature of the harm that may result from use of the device;
 - if the subject must undergo a procedure as part of the investigational study, the IRB must consider the potential harm that could be caused by the procedure in addition to the potential harm caused by the device; and
 - when applicable, the information and justification given by the sponsor for any NSR determination. Note: this must be reviewed by the IRB.
- (d) The IRB may determine a device to be SR even if the sponsor considers the device to be NSR. If the sponsor indicates that the device is NSR, but the IRB determines it to be SR, then the sponsor must obtain an Investigational Device Exemption from the FDA.
- (e) Because NSR studies do not require an IDE, a clinical investigation involving an investigational device classified by the sponsor as NSR may be submitted to an IRB for review without an IDE. The sponsor should provide the IRB with a risk assessment and the rationale used in making its NSR risk determination.
- (f) If the sponsor or FDA has determined a device to be SR, the IRB must also consider the device to be SR during the IRB review.
- (g) The rationale for the IRB's NSR/SR determination must be documented in the IRB minutes.
- (2) The IRB must initially review the risk/benefit ratio of all non-significant and significant risk devices compared to alternative devices and procedures.
- (3) Expedited Review
 - (a) Research projects involving significant risk devices do not qualify for expedited review during the initial review.
 - (b) Research projects involving significant risk devices may be considered for expedited review during the continuing review, if the IRB determines it to be consistent with the research categories published in the Federal Register, Vol. 63, No.216, 11/09/1998: Expedited review of significant risk device studies is allowed at continuing review under certain specified conditions.
- (4) The IRB must determine the frequency of review for research projects involving investigational devices.
- (5) The IRB must review the risk/benefit ratio of the device compared to alternative devices and procedures and approve or disapprove on a continual basis, research projects involving investigational devices.
- (6) The IRB may only approve significant risk device studies only after an IDE approval is obtained by the sponsor. In instances where the sponsor has appropriately obtained a 510(k) or Humanitarian Use Device designation, the IRB may only approve these studies once these approvals have been obtained and verified with the IRB.
- (7) The IRB will notify the investigator and/or sponsor of the review decisions, actions and any needed modifications regarding the research project.

VA MEDICAL CENTER, PORTLAND, OREGON
Human Research Protection Program Policy & Procedure
Investigational Device and/or Drug Usage

Effective: 8/27/2007

- (a) If a device study is submitted as SR and the IRB verifies that IDE approval has been obtained by the sponsor, the IRB does not have to notify the sponsor or investigator of the SR determination.
- (b) If the IRB determines the investigational device to be significant risk and the sponsor has not obtained IDE approval from the FDA, the IRB Coordinators will notify the sponsor and investigator of its determination in writing within ten working days of the convened meeting.
- (8) The IRB must maintain records for reviewed research project in accordance with the IRB Standard Operating Procedures, which is in accordance with 21CFR56.

c. Emergency and/or One-time Compassionate Use of Unapproved Medical Devices or Investigational Drugs:

Note: The Food and Drug Administration (FDA) recognizes that emergencies may arise where an unapproved device or drug may offer the only possible life-saving alternative, but an IDE for the device or IND for the drug does not exist, or the proposed use is not approved under an existing IDE or IND, or the physician or institution is not approved under the IDE or IND. Using its enforcement discretion, FDA has not objected if a physician chooses to use such a device or drug in an emergency situation, provided that the physician later justifies to the FDA that an emergency actually existed.

A Principal Investigator/Physician must adhere to the following procedures regarding emergency use of unapproved medical devices, investigational drugs, or unapproved use of an approved drug:

(1) Requirements for emergency use of a medical device, biologic, or drug:

Note: All three requirements must be met for justification of emergency use.

- (a) A patient is in a life-threatening or severely debilitating condition that needs immediate treatment.
- (b) There is no generally acceptable alternative available for treating the patient.
- (c) Sufficient time is not available to obtain prior FDA approval through existing procedures, prior to using the device because of the immediate need.

(2) FDA Physician Expectations Regarding Decision of Use

- (a) Determine whether all three requirements for emergency use have been met.
- (b) Assess the potential benefits from the unapproved use of the device.
- (c) Have substantial reason to believe that benefits will exist.
- (d) Decisions for “emergency” use may not be made in advance of the time of treatment made be needed based solely on the expectation the IDE or IND approval procedures may require more time than is available.
- (e) Exercise reasonable foresight with respect to potential emergencies and to make appropriate arrangements under the IDE or IND procedures far enough in advance to avoid creating a situation in which such arrangements are impracticable.

(3) Notification to the Center for Devices and Radiological Health (CDRH)

- (a) The device developer must notify the Center for Devices and Radiological Health (CDRH) Program Operation Staff immediately after the shipment is made when a device is to be used in an emergency situation meeting all justifiable requirements.
- (b) An unapproved device or drug may not be shipped in anticipation of an emergency.
- (c) Business Hour Contact Information: 301.594.1190.
- (d) Nights and weekends Contact Information: Division of Emergency and Epidemiological Operations: 202.857.8400

(4) FDA Physician Expectations regarding Subject Protection

- (a) Obtain an independent assessment by an uninvolved physician;
- (b) Obtain informed consent from the patient or the patient’s legally authorized representative;
- (c) Notify the PVAMC Chief of Staff;

VA MEDICAL CENTER, PORTLAND, OREGON
Human Research Protection Program Policy & Procedure
Investigational Device and/or Drug Usage

Effective: 8/27/2007

- (d) Notify the IRB; and
 - (e) Obtain authorization from the IDE or IND holder, if an approved IDE or IND exists for the device or drug.
- (5) **After Use Procedures**
- (a) Report the use of the unapproved medical device or drug to the IRB within five days of usage and otherwise comply with provisions of the IRB regulations;
 - (b) Evaluate the need for the device or drug in the future, and if future use is likely, obtain IRB approval and an approved IDE or IND for future use; and
 - (c) If the device or drug does have an IDE or IND, notify the sponsor of the emergency use, or if an IDE or IND does not exist, notify the FDA of the emergency use and provide the FDA with a written summary of the conditions constituting the emergency, subject protection measures, and results.

d. Waiver of Informed Consent on an Emergency Basis

Note: Even in an emergency situation, the investigator is required to obtain informed consent of the subject or the subject's legally authorized representative unless both the investigator and a physician who is not otherwise participating in the clinical investigation certify in writing the four items outlined below. [21 CFR 50.23 (a)].

- (1) An exception under FDA regulations at 21 CFR 50.23 (a) permits the emergency use of an investigational drug, device, or biologic without informed consent where the investigator and an independent physician who is not otherwise participating in the clinical investigation certify in writing all four of the following specific conditions:
 - (a) The subject is confronted by a life-threatening situation necessitating the use of the test article.
 - (b) Informed consent cannot be obtained because of an inability to communicate with, or obtain legally effective consent from the subject and there is a medical emergency or urgency.
 - (c) Time is not sufficient to obtain consent from the subject's legally authorized representative and there is a medical emergency or urgency.
 - (d) No alternative method of approved or generally recognized therapy is available that provides an equal or greater likelihood of saving the subject's life and there is a medical emergency or urgency.
- (2) If immediate use of the test article is, in the investigator's opinion, required to preserve the life of the subject, and time is not sufficient to obtain the independent determination required above in advance of using the test article, the determinations of the clinical investigator shall be made and, within 5 working days after the use of the article, be reviewed and evaluated in writing by a physician who is not participating in the clinical investigation. All of the documentation from the investigator and non-participating physician must be submitted to the IRB within 5 working days after the use of the test article. This reporting must not be construed as an approval for the emergency use by the IRB.

6. **REFERENCES:** 21CFR50
21CFR56
21CFR812
Food and Drug Administration "Guidance for Institutional Review Boards and Clinical Investigators"
Food and Drug Administration "Guidance on IDE Policies and Procedures"

7. **CONCURRENCES:** Endorsed by the Research & Development Committee <date>

8. **RESCISSION:** HRPP: Policy & Procedure No. 2, Endorsed by the R&D Committee 05/20/2002 05/19/2003, 06/28/2004 and 01/03/2005.

VA MEDICAL CENTER, PORTLAND, OREGON
Human Research Protection Program Policy & Procedure
Investigational Device and/or Drug Usage

Effective: 8/27/2007

9. **FOLLOW-UP RESPONSIBILITY:** ACOS Research & Development Service (R&D)

Michael P. Davey, M.D., Ph.D.
ACOS, Research & Development